Withings receives clearance for smart BPM
By HME News Staff
Updated 9:02 AM CST, Tue December 17, 2024
BOSTON – Withings Health Solutions, the professional health care division of Withings, has announced that its BPM Pro 2, a cellular blood pressure monitor that integrates and automates many aspects of clinical workflows, is now cleared by the U.S. Food and Drug Administration. The BPM Pro 2 is now cleared to measure blood pressure and pulse rate in adults with arm circumferences of nine to 17 inches or 16 to 20 inches. “We are thrilled BPM Pro 2 is now FDA-cleared, this device marks a significant advancement in remote patient monitoring,” said Antoine Robiliard, vice president of Withings Health Solutions. “BPM Pro 2 not only delivers precise, clinically meaningful blood pressure and pulse rate measurements but also empowers care teams with real-time insights and direct patient engagement tools.” Withings has also announced that the BPM Pro 2 has also been named a CES 2025 Innovation Awards Honoree in the digital health category. The device is designed to provide personalized health nudges from care teams (customized messages, reminders and motivational support); and seamless connectivity, allowing health care providers to access patient data on the company’s platform or their own clinical platform. Following separate clearance, BPM Pro 2’s future capabilities include a 1-lead ECG to detect atrial fibrillation (expected in 2025).
Comments